Transaction details
Director Grewal Harpreet of Penumbra Inc (NYSE:PEN) sold 100 shares of the company's common stock on April 2, 2026. The shares were disposed of at a per-share price of $328.22, producing a total transaction amount of $32,822. The filing with the Securities and Exchange Commission records that the disposition was carried out pursuant to a Rule 10b5-1 trading plan.
Position after the sale
After completing the sale, Grewal retains direct ownership of 8,719 shares of Penumbra, a stake that the filing notes includes shares subject to vesting.
Market context and valuation signals
Penumbra's stock has advanced roughly 32% over the past six months and is trading at $329.87. The company’s P/E ratio stands at 72.86. According to InvestingPro analysis cited in the filing materials, PEN appears overvalued against its Fair Value estimate.
Recent operating performance
Penumbra reported fourth-quarter 2025 revenue of $385.4 million, which exceeded both previously preannounced figures and the Street consensus of $367.7 million. Adjusted EBITDA for the quarter came in at $79.1 million versus expectations of $66.7 million.
Analyst reactions and changing ratings
Following the quarter, UBS maintained a Neutral rating on Penumbra and kept its price target at $374.00. Evercore ISI raised its price target to $360 from $340, noting embolization growth as a factor, while also indicating that U.S. thrombectomy results were below estimates amid difficult year-over-year comparisons.
In parallel, several firms adjusted their recommendations after acquisition news. Canaccord Genuity moved Penumbra from Buy to Hold while setting a $374.00 target. Baird downgraded the stock from Outperform to Neutral and likewise set a $374.00 target, representing a scenario of a higher target paired with a more cautious recommendation.
Acquisition development
Boston Scientific announced it will acquire Penumbra in a transaction that uses a mix of stock and cash, valuing PEN at $374 per share and assigning an enterprise value of approximately $14.5 billion to the combined deal.
Investor resources
The filing references availability of a Pro Research Report for PEN on InvestingPro for investors seeking deeper analysis of the company and its valuation standing.
This article presents the details of the reported insider sale, recent financial results, analyst responses, and the announced acquisition, without asserting causes beyond the documented filings and public company disclosures.